Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
Condition: Extranodal NK/T-cell Lymphoma Interventions: Biological: Sugemalimab; Drug: Placebo; Drug: Pegaspargase; Drug: Gemcitabine; Drug: Oxaliplatin Sponsor: CStone Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials